{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:03:33Z","timestamp":1769040213139,"version":"3.49.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2016,2,23]],"date-time":"2016-02-23T00:00:00Z","timestamp":1456185600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1007\/s00066-016-0950-7","type":"journal-article","created":{"date-parts":[[2016,2,23]],"date-time":"2016-02-23T06:32:57Z","timestamp":1456209177000},"page":"342-348","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Radiation recall dermatitis induced by sorafenib","Recall-Strahlendermatitis durch Sorafenib"],"prefix":"10.1007","volume":"192","author":[{"given":"Sonja","family":"Stieb","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Riesterer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cornelia","family":"Br\u00fcssow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernhard","family":"Pestalozzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Guckenberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Weiler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,2,23]]},"reference":[{"key":"950_CR1","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1634\/theoncologist.2009-0090","volume":"15","author":"HA Burris 3rd","year":"2010","unstructured":"Burris HA 3rd, Hurtig J (2010) Radiation recall with anticancer agents. Oncologist 15:1227\u20131237. doi: 10.1634\/theoncologist.2009-0090","journal-title":"Oncologist"},{"key":"950_CR2","unstructured":"Product Information: NEXAVAR(R) oral tablets, sorafenib oral tablets. Bayer HealthCare Pharmaceuticals Inc. (per FDA), Whippany, NJ, 2013"},{"key":"950_CR3","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jhep.2012.06.014","volume":"57","author":"J Bruix","year":"2012","unstructured":"Bruix J, Raoul JL, Sherman M, Mazzaferro V, Bolondi L, Craxi A, Galle PR, Santoro A, Beaugrand M, Sangiovanni A, Porta C, Gerken G, Marrero JA, Nadel A, Shan M, Moscovici M, Voliotis D, Llovet JM (2012) Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol 57:821\u2013829. doi: 10.1016\/j.jhep.2012.06.014","journal-title":"J Hepatol"},{"key":"950_CR4","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.ejca.2011.12.006","volume":"48","author":"AL Cheng","year":"2012","unstructured":"Cheng AL, Guan Z, Chen Z, Tsao CJ, Qin S, Kim JS, Yang TS, Tak WY, Pan H, Yu S, Xu J, Fang F, Zou J, Lentini G, Voliotis D, Kang YK (2012) Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial. Eur J Cancer 48:1452\u20131465. doi: 10.1016\/j.ejca.2011.12.006","journal-title":"Eur J Cancer"},{"key":"950_CR5","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/ijcp.12352","volume":"68","author":"R Lencioni","year":"2014","unstructured":"Lencioni R, Kudo M, Ye SL, Bronowicki JP, Chen XP, Dagher L, Furuse J, Geschwind JF, de Guevara LL, Papandreou C, Takayama T, Yoon SK, Nakajima K, Lehr R, Heldner S, Sanyal AJ (2014) GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis. Int J Clin Pract 68:609\u2013617. doi: 10.1111\/ijcp.12352","journal-title":"Int J Clin Pract"},{"key":"950_CR6","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE v4.0). http:\/\/evs.nci.nih.gov"},{"key":"950_CR7","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.radonc.2013.07.003","volume":"109","author":"S Laban","year":"2013","unstructured":"Laban S, Steinmeister L, Gleissner L, Grob TJ, Grenman R, Petersen C, Gal A, Knecht R, Dikomey E, Kriegs M (2013) Sorafenib sensitizes head and neck squamous cell carcinoma cells to ionizing radiation. Radiother Oncol 109:286\u2013292. doi: 10.1016\/j.radonc.2013.07.003","journal-title":"Radiother Oncol"},{"key":"950_CR8","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1177\/030089161309900210","volume":"99","author":"YK Jeong","year":"2013","unstructured":"Jeong YK, Kim MS, Lee JY, Kim EH, Kim W, Ha H, Jeong JH (2013) Sorafenib acts synergistically in combination with radiotherapy without causing intestinal damage in colorectal cancer. Tumori 99:176\u2013182. doi: 10.1700\/1283.14189","journal-title":"Tumori"},{"key":"950_CR9","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ijrobp.2013.01.025","volume":"86","author":"CY Huang","year":"2013","unstructured":"Huang CY, Lin CS, Tai WT, Hsieh CY, Shiau CW, Cheng AL, Chen KF (2013) Sorafenib enhances radiation-induced apoptosis in hepatocellular carcinoma by inhibiting STAT3. Int J Radiat Oncol Biol Phys 86:456\u2013462. doi: 10.1016\/j.ijrobp.2013.01.025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"950_CR10","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.canlet.2012.10.024","volume":"329","author":"W Yu","year":"2013","unstructured":"Yu W, Gu K, Yu Z, Yuan D, He M, Ma N, Lai S, Zhao J, Ren Z, Zhang X, Shao C, Jiang GL (2013) Sorafenib potentiates irradiation effect in hepatocellular carcinoma in vitro and in vivo. Cancer Lett 329:109\u2013117. doi: 10.1016\/j.canlet.2012.10.024","journal-title":"Cancer Lett"},{"key":"950_CR11","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.3892\/or.2014.3497","volume":"32","author":"EH Kim","year":"2014","unstructured":"Kim EH, Kim MS, Jung WG (2014) The mechanisms responsible for the radiosensitizing effects of sorafenib on colon cancer cells. Oncol Rep 32:2421\u20132428. doi: 10.3892\/or.2014.3497","journal-title":"Oncol Rep"},{"key":"950_CR12","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1200\/JCO.2007.15.8451","volume":"26","author":"NA Peters","year":"2008","unstructured":"Peters NA, Richel DJ, Verhoeff JJ, Stalpers LJ (2008) Bowel perforation after radiotherapy in a patient receiving sorafenib. J Clin Oncol 26:2405\u20132406. doi: 10.1200\/JCO.2007.15.8451","journal-title":"J Clin Oncol"},{"key":"950_CR13","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J, Group SIS (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378\u2013390. doi: 10.1056\/NEJMoa0708857","journal-title":"N Engl J Med"},{"key":"950_CR14","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.ijrobp.2014.01.017","volume":"88","author":"SW Chen","year":"2014","unstructured":"Chen SW, Lin LC, Kuo YC, Liang JA, Kuo CC, Chiou JF (2014) Phase 2 study of combined sorafenib and radiation therapy in patients with advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 88:1041\u20131047. doi: 10.1016\/j.ijrobp.2014.01.017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"950_CR15","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1038\/bjc.2014.209","volume":"110","author":"AF Hottinger","year":"2014","unstructured":"Hottinger AF, Aissa AB, Espeli V, Squiban D, Dunkel N, Vargas MI, Hundsberger T, Mach N, Schaller K, Weber DC, Bodmer A, Dietrich PY (2014) Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma. Br J Cancer 110:2655\u20132661. doi: 10.1038\/bjc.2014.209","journal-title":"Br J Cancer"},{"key":"950_CR16","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.ijrobp.2012.04.017","volume":"85","author":"RB Den","year":"2013","unstructured":"Den RB, Kamrava M, Sheng Z, Werner-Wasik M, Dougherty E, Marinucchi M, Lawrence YR, Hegarty S, Hyslop T, Andrews DW, Glass J, Friedman DP, Green MR, Camphausen K, Dicker AP (2013) A phase I study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas. Int J Radiat Oncol Biol Phys 85:321\u2013328. doi: 10.1016\/j.ijrobp.2012.04.017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"950_CR17","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ijrobp.2014.02.024","volume":"89","author":"EG Chiorean","year":"2014","unstructured":"Chiorean EG, Schneider BP, Akisik FM, Perkins SM, Anderson S, Johnson CS, DeWitt J, Helft P, Clark R, Johnston EL, Spittler AJ, Deluca J, Bu G, Shahda S, Loehrer PJ, Sandrasegaran K, Cardenes HR (2014) Phase 1 pharmacogenetic and pharmacodynamic study of sorafenib with concurrent radiation therapy and gemcitabine in locally advanced unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 89:284\u2013291. doi: 10.1016\/j.ijrobp.2014.02.024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"950_CR18","doi-asserted-by":"crossref","first-page":"e82209","DOI":"10.1371\/journal.pone.0082209","volume":"9","author":"J Aparicio","year":"2014","unstructured":"Aparicio J, Garcia-Mora C, Martin M, Petriz ML, Feliu J, Sanchez-Santos ME, Ayuso JR, Fuster D, Conill C, Maurel J (2014) A phase I, dose-finding study of sorafenib in combination with gemcitabine and radiation therapy in patients with unresectable pancreatic adenocarcinoma: a Grupo Espanol Multidisciplinario en Cancer Digestivo (GEMCAD) study. PLoS One 9:e82209. doi: 10.1371\/journal.pone.0082209","journal-title":"PLoS One"},{"key":"950_CR19","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1245\/s10434-014-3543-7","volume":"21","author":"RJ Canter","year":"2014","unstructured":"Canter RJ, Borys D, Olusanya A, Li CS, Lee LY, Boutin RD, Christensen SD, Tamurian RM, Monjazeb AM (2014) Phase I trial of neoadjuvant conformal radiotherapy plus sorafenib for patients with locally advanced soft tissue sarcoma of the extremity. Ann Surg Oncol 21:1616\u20131623. doi: 10.1245\/s10434-014-3543-7","journal-title":"Ann Surg Oncol"},{"key":"950_CR20","doi-asserted-by":"crossref","first-page":"6902","DOI":"10.1158\/1078-0432.CCR-13-1594","volume":"19","author":"JM Meyer","year":"2013","unstructured":"Meyer JM, Perlewitz KS, Hayden JB, Doung YC, Hung AY, Vetto JT, Pommier RF, Mansoor A, Beckett BR, Tudorica A, Mori M, Holtorf ML, Afzal A, Woodward WJ, Rodler ET, Jones RL, Huang W, Ryan CW (2013) Phase I trial of preoperative chemoradiation plus sorafenib for high-risk extremity soft tissue sarcomas with dynamic contrast-enhanced MRI correlates. Clin Cancer Res 19:6902\u20136911. doi: 10.1158\/1078-0432.CCR-13-1594","journal-title":"Clin Cancer Res"},{"key":"950_CR21","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1097\/CAD.0000000000000108","volume":"25","author":"K Bramswig","year":"2014","unstructured":"Bramswig K, Ploner F, Martel A, Bauernhofer T, Hilbe W, Kuhr T, Leitgeb C, Mlineritsch B, Petzer A, Seebacher V, Stoger H, Girschikofsky M, Hochreiner G, Ressler S, Romeder F, Woll E, Brodowicz T (2014) Sorafenib in advanced, heavily pretreated patients with soft tissue sarcomas. Anticancer Drugs 25:848\u2013853. doi: 10.1097\/CAD.0000000000000108","journal-title":"Anticancer Drugs"},{"key":"950_CR22","unstructured":"WHO Global Database of Individual Case Safety Reports in Pharmacovigilance VigiBase\u00ae. https:\/\/adr.who-umc.org\/"},{"key":"950_CR23","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.2147\/OTT.S64706","volume":"7","author":"CH Hsieh","year":"2014","unstructured":"Hsieh CH, Lin SC, Shueng PW, Kuo DY (2014) Recall radiation dermatitis by sorafenib following stereotactic body radiation therapy. Onco Targets Ther 7:1111\u20131114. doi: 10.2147\/OTT.S64706","journal-title":"Onco Targets Ther"},{"key":"950_CR24","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3857\/roj.2013.31.3.171","volume":"31","author":"D Oh","year":"2013","unstructured":"Oh D, Park HC, Lim HY, Yoo BC (2013) Sorafenib-triggered radiation recall dermatitis with a disseminated exanthematous reaction. Radiat Oncol J 31:171\u2013174. doi: 10.3857\/roj.2013.31.3.171","journal-title":"Radiat Oncol J"},{"key":"950_CR25","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/CAD.0b013e328333d679","volume":"21","author":"C Chung","year":"2010","unstructured":"Chung C, Dawson LA, Joshua AM, Brade AM (2010) Radiation recall dermatitis triggered by multi-targeted tyrosine kinase inhibitors: sunitinib and sorafenib. Anticancer Drugs 21:206\u2013209. doi: 10.1097\/CAD.0b013e328333d679","journal-title":"Anticancer Drugs"},{"key":"950_CR26","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3747\/co.2008.201","volume":"15","author":"AE Hird","year":"2008","unstructured":"Hird AE, Wilson J, Symons S, Sinclair E, Davis M, Chow E (2008) Radiation recall dermatitis: case report and review of the literature. Curr Oncol 15:53\u201362","journal-title":"Curr Oncol"},{"key":"950_CR27","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/S0959-8049(96)00461-3","volume":"33","author":"W Yeo","year":"1997","unstructured":"Yeo W, Leung SF, Johnson PJ (1997) Radiation-recall dermatitis with docetaxel: establishment of a requisite radiation threshold. Eur J Cancer 33:698\u2013699","journal-title":"Eur J Cancer"},{"key":"950_CR28","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1002\/1097-0142(19930215)71:4<1322::AID-CNCR2820710425>3.0.CO;2-Z","volume":"71","author":"KJ Stelzer","year":"1993","unstructured":"Stelzer KJ, Griffin TW, Koh WJ (1993) Radiation recall skin toxicity with bleomycin in a patient with Kaposi sarcoma related to acquired immune deficiency syndrome. Cancer 71:1322\u20131325","journal-title":"Cancer"},{"key":"950_CR29","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1002\/1097-0142(197602)37:2+<1186::AID-CNCR2820370830>3.0.CO;2-V","volume":"37","author":"TL Phillips","year":"1976","unstructured":"Phillips TL, Fu KK (1976) Quantification of combined radiation therapy and chemotherapy effects on critical normal tissues. Cancer 37:1186\u20131200","journal-title":"Cancer"},{"key":"950_CR30","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1200\/JCO.2005.06.124","volume":"23","author":"D Strumberg","year":"2005","unstructured":"Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M, Faghih M, Brendel E, Voliotis D, Haase CG, Schwartz B, Awada A, Voigtmann R, Scheulen ME, Seeber S (2005) Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23:965\u2013972. doi: 10.1200\/JCO.2005.06.124","journal-title":"J Clin Oncol"},{"key":"950_CR31","doi-asserted-by":"crossref","first-page":"4130","DOI":"10.1200\/JCO.2002.99.148","volume":"20","author":"R Camidge","year":"2002","unstructured":"Camidge R, Price A (2002) Radiation recall dermatitis may represent the Koebner phenomenon. J Clin Oncol 20:4130, author reply 4130","journal-title":"J Clin Oncol"},{"key":"950_CR32","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1532-429X-16-25","volume":"16","author":"SC Masri","year":"2014","unstructured":"Masri SC, Misselt AJ, Dudek A, Konety SH (2014) Radiation recall reaction causing cardiotoxicity. J Cardiovasc Magn Reson 16:25. doi: 10.1186\/1532-429X-16-25","journal-title":"J Cardiovasc Magn Reson"},{"key":"950_CR33","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1001\/jamadermatol.2013.4200","volume":"149","author":"L Boussemart","year":"2013","unstructured":"Boussemart L, Boivin C, Claveau J, Tao YG, Tomasic G, Routier E, Mateus C, Deutsch E, Robert C (2013) Vemurafenib and radiosensitization. JAMA Dermatol 149:855\u2013857. doi: 10.1001\/jamadermatol.2013.4200","journal-title":"JAMA Dermatol"},{"key":"950_CR34","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/CMR.0000000000000078","volume":"24","author":"A Forschner","year":"2014","unstructured":"Forschner A, Zips D, Schraml C, Rocken M, Iordanou E, Leiter U, Weide B, Garbe C, Meier F (2014) Radiation recall dermatitis and radiation pneumonitis during treatment with vemurafenib. Melanoma Res 24:512\u2013516. doi: 10.1097\/CMR.0000000000000078","journal-title":"Melanoma Res"},{"key":"950_CR35","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.jaad.2009.04.033","volume":"61","author":"JN Dauendorffer","year":"2009","unstructured":"Dauendorffer JN, Dupuy A (2009) Radiation recall dermatitis induced by erlotinib. J Am Acad Dermatol 61:1086. doi: 10.1016\/j.jaad.2009.04.033","journal-title":"J Am Acad Dermatol"},{"key":"950_CR36","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/j.ejca.2012.12.009","volume":"49","author":"A Levy","year":"2013","unstructured":"Levy A, Hollebecque A, Bourgier C, Loriot Y, Guigay J, Robert C, Delaloge S, Bahleda R, Massard C, Soria JC, Deutsch E (2013) Targeted therapy-induced radiation recall. Eur J Cancer 49:1662\u20131668. doi: 10.1016\/j.ejca.2012.12.009","journal-title":"Eur J Cancer"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-016-0950-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00066-016-0950-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-016-0950-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T21:58:27Z","timestamp":1567634307000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00066-016-0950-7"}},"subtitle":["A case study and review of the literature","Eine Fallstudie und Literatur\u00fcbersicht"],"short-title":[],"issued":{"date-parts":[[2016,2,23]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["950"],"URL":"https:\/\/doi.org\/10.1007\/s00066-016-0950-7","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"value":"0179-7158","type":"print"},{"value":"1439-099X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,23]]}}}